Profile data is unavailable for this security.
About the company
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
- Revenue in EUR (TTM)2.22bn
- Net income in EUR387.01m
- Incorporated--
- Employees4.46k
- LocationRecordati Industria Chimica e Farmaceutica SpAVia Matteo Civitali, 1MILANO 20148ItalyITA
- Phone+39 2487871
- Fax+39 240073747
- Websitehttps://recordati.com/
More ▼
Mergers & acquisitions
| Acquired company | REC:MIL since announced | Transaction value |
|---|---|---|
| European Medicines Agency | 4.55% | 110.31m |
Data delayed at least 15 minutes, as of Nov 05 2024 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen SA | 3.44bn | 663.90m | 9.43bn | 5.33k | 14.16 | 2.30 | 9.18 | 2.74 | 7.94 | 8.15 | 41.11 | 48.94 | 0.5436 | 1.98 | 5.02 | 645,089.20 | 10.47 | 9.71 | 14.29 | 13.33 | 82.01 | 82.76 | 19.27 | 16.02 | 0.9771 | 46.18 | 0.0902 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
| Catalent Inc | 4.03bn | -958.86m | 9.79bn | 16.90k | -- | 2.95 | -- | 2.43 | -5.75 | -5.75 | 24.14 | 19.91 | 0.4268 | 4.88 | 3.01 | 259,230.80 | -10.16 | 0.0124 | -11.61 | 0.014 | 21.75 | 28.93 | -23.81 | 0.0278 | 1.93 | 0.6681 | 0.5765 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
| Sichuan Biokin Pharmaceutical Co Ltd | 757.10m | 492.06m | 9.90bn | 2.09k | 20.12 | 18.03 | -- | 13.08 | 9.48 | 9.48 | 14.58 | 10.58 | 1.40 | 1.81 | 64.16 | 2,802,843.00 | 90.79 | -- | 138.20 | -- | 95.33 | -- | 64.99 | -- | 2.89 | -- | 0.2807 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
| Swedish Orphan Biovitrum AB (publ) | 2.18bn | 301.27m | 10.23bn | 1.81k | 33.33 | 3.10 | 16.58 | 4.69 | 10.06 | 10.06 | 72.98 | 108.01 | 0.3443 | 1.37 | 5.72 | 14,353,840.00 | 4.75 | 5.93 | 5.85 | 7.60 | 78.60 | 77.42 | 13.81 | 16.61 | 0.6225 | 4.35 | 0.325 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Recordati Industria Chmc Frmctc SpA | 2.22bn | 387.01m | 10.85bn | 4.46k | 29.11 | 5.93 | 20.02 | 4.88 | 1.78 | 1.78 | 10.31 | 8.75 | 0.5289 | 1.76 | 4.96 | 499,152.90 | 9.20 | 11.67 | 11.78 | 15.02 | 67.10 | 70.43 | 17.40 | 21.45 | 0.9457 | 6.74 | 0.4818 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Lupin Ltd | 2.27bn | 247.32m | 10.91bn | 21.87k | 44.21 | -- | 30.29 | 4.80 | 49.50 | 49.50 | 454.84 | -- | -- | -- | -- | 9,510,284.00 | -- | 1.43 | -- | 2.22 | 67.58 | 58.52 | 11.00 | 2.04 | -- | 9.07 | -- | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Zydus Lifesciences Ltd | 2.25bn | 455.46m | 11.04bn | 26.24k | 24.34 | -- | 20.29 | 4.90 | 41.28 | 41.51 | 204.01 | -- | -- | -- | -- | 7,856,441.00 | -- | 9.05 | -- | 14.01 | 70.22 | 61.15 | 20.29 | 14.33 | -- | -- | -- | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Dr Reddy's Laboratories Ltd | 3.16bn | 608.08m | 11.54bn | 26.34k | 19.00 | -- | 14.96 | 3.65 | 66.74 | 66.74 | 347.18 | -- | -- | -- | -- | 10,989,370.00 | -- | 11.37 | -- | 16.02 | 70.80 | 65.86 | 19.22 | 14.63 | -- | 36.60 | -- | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Biomarin Pharmaceutical Inc | 2.53bn | 296.29m | 11.57bn | 3.40k | 39.70 | 2.32 | 29.81 | 4.57 | 1.66 | 1.66 | 14.02 | 28.41 | 0.4046 | 0.5242 | 4.08 | 809,411.60 | 4.74 | 0.7116 | 5.49 | 0.8079 | 78.95 | 76.30 | 11.71 | 2.05 | 2.62 | -- | 0.099 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Shionogi & Co Ltd | 2.53bn | 934.01m | 11.73bn | 4.96k | 12.08 | 1.44 | 11.22 | 4.64 | 180.70 | 180.70 | 489.15 | 1,519.70 | 0.292 | 0.9189 | 2.94 | 84,393,830.00 | 10.69 | 12.57 | 11.94 | 14.24 | 85.70 | 84.43 | 36.62 | 37.91 | 6.48 | -- | 0.0088 | 26.77 | 1.97 | 3.41 | -12.40 | 3.38 | 2.17 | 11.22 |
| Beijing Wantai Biolog Pha Ent Co Ltd | 322.43m | -38.08m | 11.79bn | 3.84k | -- | 7.33 | -- | 36.56 | -0.2393 | -0.2393 | 1.97 | 9.82 | 0.1596 | 0.7843 | 0.7758 | 647,931.10 | -1.89 | 24.08 | -2.26 | 31.80 | 69.01 | 85.18 | -11.84 | 34.95 | 4.18 | -- | 0.0238 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
| Torrent Pharmaceuticals Ltd | 1.23bn | 196.93m | 11.84bn | 14.92k | 60.10 | 14.44 | 41.65 | 9.65 | 53.25 | 53.25 | 331.63 | 221.72 | 0.7525 | 1.22 | 6.35 | 7,525,369.00 | 12.08 | 8.34 | 17.95 | 13.03 | 75.52 | 71.78 | 16.06 | 13.18 | 0.7444 | 9.32 | 0.2941 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Mankind Pharma Ltd | 1.16bn | 214.43m | 11.96bn | 19.54k | 55.84 | -- | 45.42 | 10.27 | 48.91 | 48.91 | 265.43 | -- | -- | -- | -- | 5,450,142.00 | -- | -- | -- | -- | 69.93 | -- | 18.69 | -- | -- | 90.42 | -- | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Hansoh Pharmaceutical Group Company Ltd | 1.56bn | 608.92m | 12.54bn | 9.10k | 20.84 | 3.48 | 18.99 | 8.02 | 0.8568 | 0.8568 | 2.19 | 5.13 | 0.3804 | 1.81 | 3.89 | 1,448,172.00 | 14.82 | 11.58 | 17.87 | 13.98 | 91.01 | 90.78 | 38.97 | 29.28 | 7.81 | -- | 0.0043 | 12.75 | 7.69 | 5.52 | 26.85 | 11.49 | -10.45 | -- |
| Viatris Inc | 14.01bn | -594.35m | 12.56bn | 38.00k | -- | 0.70 | 6.34 | 0.8968 | -0.5433 | -0.5433 | 12.68 | 16.36 | 0.3242 | 2.30 | 5.25 | 401,031.60 | -1.38 | 0.0887 | -1.62 | 0.1061 | 42.78 | 40.29 | -4.24 | 0.2891 | 1.02 | 2.48 | 0.4668 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Data as of Nov 05 2024. Currency figures normalised to Recordati Industria Chimica e Farmaceutica SpA's reporting currency: Euro EUR
14.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 06 Sep 2024 | 7.62m | 3.65% |
| Invesco Asset Management Ltd.as of 22 Apr 2024 | 4.76m | 2.28% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 3.53m | 1.69% |
| Fundsmith LLPas of 22 Apr 2024 | 3.00m | 1.44% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 2.53m | 1.21% |
| Mawer Investment Management Ltd.as of 30 Jun 2024 | 2.35m | 1.12% |
| Norges Bank Investment Managementas of 22 Apr 2024 | 2.19m | 1.05% |
| Financi�re de l'�chiquier SAas of 22 Apr 2024 | 2.08m | 1.00% |
| Geode Capital Management LLCas of 31 Oct 2024 | 1.68m | 0.81% |
| Invesco Advisers, Inc.as of 22 Apr 2024 | 1.25m | 0.60% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
